Drug Trial Radar · NCT05134571
China Post-marketing Surveillance (PMS) Study of Aldurazyme®
Last checked: Nov 20, 2026Latest source record: Sep 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
12
Actual
Start
Oct 28, 2021
Primary completion
Jul 26, 2023
Study completion Jul 26, 2023
Sponsor
- Lead sponsor
- Genzyme, a Sanofi CompanySanofi (SNY)
- Sponsor type
- Industry
- First posted
- Nov 26, 2021
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 5 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a single treatment arm study that is open-label to be conducted in Chinese participants with MPS I. Trial Objectives are to evaluate the safety and tolerability of Aldurazyme in Chinese MPS I participants, and to evaluate the efficacy of Aldurazyme on the percent change of urinary glycosaminoglycans (uGAGs) from baseline to Week 26. The study will also evaluate the effect on uGAG level and liver volume (hepatomegaly) after 26 weeks, with Aldurazyme treatment in Chinese MPS I participants. Treatment duration will include: 2 weeks of screening, 26 weeks of treatment and 1 week of follow-up period. During the treatment period, weekly visits are designed to accommodate weekly administration of Aldurazyme (laronidase).
Conditions
- Mucopolysaccharidosis I
Interventions
LaronidaseDrug
Solution for injection; Intravenous
Primary outcomes
What the sponsor says the trial is designed to measure.
- Participants with adverse events (AEs)Time frame: Baseline to Week 27
- The incidence of Potentially clinically significant abnormality (PCSA) analyses for clinical laboratory, vital signs, and ECG parameters during the TE periodTime frame: Baseline to Week 27
- The percent change of uGAGsTime frame: Baseline to Week 26
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
Investigational Site Number :1560003
Beijing, China
Investigational Site Number :1560002
Beijing, China
Investigational Site Number :1560004
Guangzhou, China
Investigational Site Number :1560006
Hangzhou, China
Investigational Site Number :1560001
Wuhan, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.